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Abstract 35 
Background: Battery replacement or revision surgery for neuromodulation implants is 36 
conventionally performed using sharp dissection. Meticulous dissection within thick scar 37 
tissue is vital to avoid damage to surrounding lead(s) which could result in more extensive 38 
revision surgery. Traditional electrosurgery devices are contraindicated as the emitted energy 39 
can be transferred to the hardware resulting in implant or tissue damage with severe 40 
consequent complications.  41 
Objective: We report our experience and potential applications of a novel, pulsed monopolar 42 
radiofrequency energy device (PEAK PlasmaBlade™, Medtronic plc) which facilitates 43 
dissection around implants without the risk of damaging or transmitting energy through the 44 
system.   45 
Methods: A two-centre retrospective study to review the indications, safety and efficacy of 46 
the PlasmaBlade in 57 cases requiring either neuromodulation system replacement or 47 
revision. Deep brain stimulator (DBS) battery replacements were undertaken in 45 cases, 8 48 
vagal nerve stimulator battery revisions, 2 intrathecal baclofen system revision, 1 DBS 49 
extension revision and 1 DBS scar revision around the cranial portion of the lead.   50 
Results: All cases proceeded without adverse event, damage to lead/generator and with a 51 
subjective and objective impression of significant time savings. Average operating times for 52 
battery replacements were reduced from 37 to 26 minutes (p=0.015).  53 
Conclusion: In our experience, the PlasmaBlade is safe to use in revising/replacing 54 
neuromodulation implants. We observed no damage or transmission of energy to the implants 55 
or leads; additional advantages of the system include reduced operating times, less damage to 56 
surrounding tissue and the potential to facilitate revision procedures in awake patients under 57 
local anaesthesia.  58 
 59 
 60 
 61 
 62 
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Introduction 64 
Neuromodulation system implantations continue to rise annually with now over 100,000 deep 65 
brain stimulators alone implanted worldwide. Accordingly, demand for replacement of 66 
implanted pulse generators (IPG) and revision of neuromodulation systems is expected to 67 
increase over the next few decades.  68 
Conventionally, IPG replacement is performed using sharp dissection through scar tissue.  69 
This technique carries the risk of damaging the electrode leads, subsequently requiring a 70 
more extensive, invasive and expensive procedure, and putting the patient at greater risk of 71 
adverse sequelae. Monopolar electrosurgery and diathermy devices, which could facilitate 72 
dissection around electrode leads, are contraindicated as the energy from these devices can be 73 
transferred to the implanted system, damaging either the hardware or leads, and resulting in 74 
tissue damage and severe consequent complications 1-4.  75 
Comparatively, the PEAK PlasmaBlade™ (Figure 1) is a novel surgical device which 76 
delivers high frequency pulses of radiofrequency (RF) energy to induce electrical plasma 77 
along the edge of a thin (12.5µm), 99.5% insulated electrode. As the system operates at a 78 
much lower temperature than traditional monopolar electrosurgery (40 - 170°C vs. 200 - 79 
350°C) and melting point of the coatings of neurostimulation electrodes (188° C) or 80 
intrathecal catheters (200-210° C) 5, the risk of damage to the hardware or leads as 81 
demonstrated in its use with cardiac implantable electronic devices (CIEDs), including 82 
pacemakers and defibrillators, is significantly lower 6.   83 
Similar to traditional electrosurgery devices, two modes are available for the PlasmaBlade, 84 
CUT and COAG. Typically, the CUT mode (range 4 – 5) which also has haemostatic 85 
properties is utilised when dissecting around leads and hardware. Dissection around the leads 86 
is performed in parallel rather than perpendicular direction. COAG mode is not 87 
recommended in close proximity to any IPG components.  88 
We report our experience of the PlasmaBlade™ with a variety of implants including 89 
intrathecal baclofen (ITB) drug delivery system, deep brain (DBS) and vagal nerve 90 
stimulators (VNS).  91 
 92 
 93 
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METHODS 94 
We conducted a retrospective review at two neurosurgical centres (King's College Hospital 95 
London & University Hospitals Birmingham, UK) to evaluate the indications, safety and 96 
efficacy of the PEAK PlasmaBlade™ for replacement or revision of a variety of 97 
neuromodulation implants. Prior to the introduction of this device all such procedures were 98 
undertaken using traditional sharp dissection techniques. Subsequent introduction of the 99 
device at both centres led to the adoption of PlasmaBlade for all such cases.  This change of 100 
practice forms the basis of this review rather than a trial with data compared from the 101 
historical group whom had traditional dissection methods versus the cohort who subsequently 102 
had procedures undertaken with PlasmaBlade.  103 
Our PlasmaBlade cohort consisted of a variety neuromodulation implants (Table 1) and was 104 
undertaken between December 2014 and August 2017 by both trainee and consultant 105 
neurosurgeons. The indication for implantable pulse generator (IPG) replacement was 106 
depletion; lead revision was undertaken for lead failure with high impedance on telemetry. In 107 
one case, scar revision around a DBS lead and anchoring device (Stimloc, Medtronic plc) was 108 
performed to remove a reactive granuloma. All generators are commercially available 109 
(Medtronic plc, St Jude Medical, LivaNova).  110 
We investigated if any lead damage, generator or lead malfunction, haematomas or infections 111 
occurred within 30 days of the procedure. Follow up assessments included a wound 112 
examination as well as generator interrogation and lead impedance check to ensure no 113 
delayed malfunction.  114 
RESULTS 115 
Study Population 116 
Fifty seven (57) patients underwent procedures on their neuromodulation implants using the 117 
PlasmaBlade. Of these thirty eight (38) patients underwent IPG/ITB replacement under local 118 
anaesthesia. Indications, type of anaesthesia and device manufacturer are detailed in Table 1.  119 
 120 
There were no occurrences of lead or implant damage/failure using the PlasmaBlade, nor did 121 
we observe any haematomas or wound infections. Where performed under local anaesthesia 122 
the patients tolerated the procedure well enough to be discharged the same day.  123 
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Compared to equivalent numbers of patients who underwent  IPG replacement, the time taken 124 
for this procedure using PlasmaBlade was statistically significantly shorter compared to sharp 125 
dissection techniques (25.6 vs. 36.7 minutes, p=0.015). In addition to the objective outcomes, 126 
each surgeon also felt more comfortable and confident in performing the procedure with the 127 
PlasmaBlade™ in the knowledge that damage to the leads was minimal and consequently, 128 
subjectively felt that operating times were reduced.  129 
DISCUSSION 130 
Traditionally IPG replacement and neuromodulation implant hardware revisions are 131 
performed using sharp dissection techniques assisted with bipolar electrosurgery devices to 132 
control bleeding. Meticulous technique has to be employed when dissecting through thick 133 
fibrotic scar tissue to avoid damaging embedded leads. This can be challenging and time 134 
consuming if the leads have been unconventionally implanted anterior to the device or 135 
extensive dissection is required to revise larger proportions of the hardware, (e.g. spinal cord 136 
stimulators) increasing the risk of iatrogenic damage.  In our series, use of the PlasmaBlade 137 
has demonstrated a number of advantages over traditional methodology.  138 
Energy transfer / damage to hardware: We observed no damage to leads or hardware, or 139 
transference of energy via the hardware to tissues at short interval (30 days) or where 140 
available longer term follow-up of up to 24 months. Direct contact with traditional monopolar 141 
or bipolar electrosurgery is considered contraindicated4, though Ng et al have reported their 142 
experience of using the ultra-sharp monopolar tip restricted to the insulated portion of VNS 143 
leads to assist removal7.   In our experience, no issues were identified when using the 144 
PlasmaBlade tip to make direct contact with the non-insulated portions of hardware in order 145 
to dissect free the scar tissue surrounding the device (Figure 2).  We believe this is due to the 146 
design of the device, as detailed above.  147 
Weisberg et al8 compared the effects of the PlasmaBlade with conventional electrosurgery 148 
instruments in vivo and noted that polyurethane and copolymer materials are highly 149 
susceptible to thermal damage when subjected to exposure to the latter and that PlasmaBlade 150 
greatly reduces the risk of thermal damage to these materials regardless of mode or 151 
orientation of approach on both naked and microscopic examination (Figure 3).  152 
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Rarely IPGs have been noted to migrate (e.g. behind breast adipose tissue in chest 153 
implantations) making the dissection for replacement more difficult. Exposure of the IPG 154 
could be easily facilitated using the PlasmaBlade. 155 
Reduced operating time: Eliminating the risk of hardware damage using the PlasmaBlade has 156 
afforded the surgeons in this review significantly reduced apprehension customary to these 157 
procedures. Furthermore the ability to cut down directly from the skin to the hardware, 158 
essentially as a single layer, reduces the number of instrument exchanges needed at surgery. 159 
Consequently, these allowed for decreased operating times in our series compared with 160 
traditional techniques.   161 
Local anaesthesia: IPG/intrathecal drug delivery system replacement under local anaesthesia, 162 
though feasible, has the potential in patients with movement disorders to be challenging. This 163 
is especially so after repeated battery changes when the scar may be particularly thick and 164 
extensive, making surgery under local anaesthesia lengthy and uncomfortable. The design of 165 
the PlasmaBlade electrode allows the device to cut the skin safely and function continuously, 166 
even when completely submerged in aqueous solution or liquefied fat – environments where 167 
traditional electrosurgical devices suffer performance degradation. Thus, the functionality 168 
and reduced operating times with the PlasmaBlade have allowed for the procedure to be 169 
tolerable and performed under local anaesthetic and on a daycase basis. This is advantageous 170 
for ageing patients with medical co-morbidities unsuitable for general anaesthesia, as well as 171 
improving theatre efficiency by reducing the overall time taken for the procedure by 172 
eliminating intubation and cost of anaesthesia medications.  173 
Decreased bleeding & infection: Sharp dissection techniques increases the risk of ooze from 174 
the surgical cavity – especially when extensive dissection is required to expose surrounding 175 
wires – increasing the risk of post-operative pocket haematoma. Use of the PlasmaBlade 176 
reduces this risk5 and, by extension, may influence the risk of infection that has been linked 177 
to haematoma formation 9.  178 
With time, implants become surrounded by a fibrotic capsule and biofilm 10 which may 179 
harbour microbial organisms in up to 45% of cases without clinical manifestation of infection 180 
11
.  IPG replacement is known to be associated with three-fold increased risk of infection 181 
compared with the primary implant operation 12. This may be due to mechanical 'insult' to the 182 
biofilm resulting in the release of microbial organisms, immunological defences being 183 
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overwhelmed and ultimately conversion of colonisation to overt infection. For this reason 184 
some physicians undertaking cardiac pacemaker implant replacement advocate complete 185 
removal of capsule surrounding the generator and lead with resultant lower infection rates 6. 186 
Though this practice is not routinely undertaken with neurostimulators,  Servello et al13 have 187 
recently reported their experience of capsulectomy in 10 cases during IPG replacement using 188 
the PlasmaBlade. They conclude that similar to our experience, capuslectomy as a means of 189 
preventing infection was greatly facilitated by the PlasmaBlade, which otherwise would be 190 
difficult with traditional surgical instruments.  191 
Decreased smoke: Given the concerns of inhaling smoke plume intra-operatively 14, the CUT 192 
mode of PlasmaBlade has the advantage of significantly reduced smoke compared with 193 
traditional electrosurgery (1.8 vs. 38.7 mg average mass of smoke particulate). 194 
Capsule dissection and cavity exposure: New models of VNS have allowed for closed-loop 195 
stimulation using the Cardiac Sensing Model 106 (Cyberonics). This model has the 196 
disadvantage of being larger than older generations (Models 103 & 104). Thus, during 197 
replacement of the latter with the larger models, extensive capsule dissection and exposure 198 
must be performed to allow for satisfactory positioning of the IPG within the cavity, without 199 
damaging leads embedded within the capsule. In our experience this is significantly easier, 200 
safer and quicker using PlasmaBlade. 201 
Improved healing: As the operating temperature of the PlasmaBlade is lower, healing has 202 
been noted to be improved compared with traditional electrosurgery devices with 203 
significantly less acute thermal damage and inflammatory response 15 (Figure 4). This has the 204 
potential for improved post-operative wound healing with histologic scoring for injury and 205 
wound strength revealing equivalence with scalpel incisions but three fold increased strength 206 
compared with conventional electrosurgery 5. Beside applications in functional neurosurgery, 207 
this could prove an advantage in neurosurgical cases where CSF fistula from poor wound 208 
healing is an issue (e.g. posterior fossa approaches, spinal intradural cases) or for complex 209 
shunt revisions, though well designed trials would be required to prove this.  210 
 211 
Efficiency & expense: Operating room costs form a large burden on the healthcare system 212 
with typical costs of running a theatre in the UK ranging from £600 to £960 per hour16. 213 
Unfortunately, theatre inefficiency is a well recognised source of financial waste with a 214 
single-centre service evaluation reported potential savings of approximately £3000/day in its 215 
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hospital if delays of only 16 min per operation could be avoided17.  Our review has confirmed 216 
a significant reduction in operating times using the PlasmaBlade allowing for greater 217 
efficiency and improved utilisation of theatre time. We estimate that on average per list we 218 
have been able to undertake an extra battery change increasing remuneration of up to £1000 219 
per list. Further, the consequence of lead damage during battery replacement carries 220 
significant morbidity and mortality risk, including increased length of stay and serious 221 
financial implications averaging between £5000 and £20,000 per incident depending on the 222 
parts of the hardware damaged18. Improved efficiency combined with this potential to reduce 223 
complications has the potential to provide significant cost savings 6. 224 
Surgical practioners: As the number of patients requiring IPG replacements increase 225 
annually, elimination of the risk of inadvertent damage and potential for reduced 226 
haematoma/infection could allow for a more cost effective option of training surgical 227 
practioners to undertake the procedure.  228 
General applications: Patients with neuromodulating systems in situ may require unrelated 229 
surgery for a variety of reasons e.g. it is not uncommon for patients with Parkinson's disease 230 
treated with DBS to require lumbar spine surgery for degenerative spine disease. Given the 231 
contraindication of monopolar diathermy usage in patients with neuromodulation implants, 232 
sharp dissecting techniques need to be applied which can lead to increase blood loss and 233 
prolonged operation. PlasmaBlade can be safely substituted for conventional diathermy in 234 
these patients, providing the surgeons with a greater repertoire of instruments to achieve their 235 
goals.   236 
Though we report on a relatively small number of cases operated upon using the 237 
PlasmaBlade, this technology represents a major advance in surgical tool design. It is 238 
expected that this will feature as a regular tool in the armamentarium of neurosurgeons 239 
undertaking IPG replacement/ hardware revision given the advantages over traditional 240 
electrosurgical devices.  241 
CONCLUSION 242 
In our experience, use of the PlasmaBlade for IPG changes and hardware revisions was safe 243 
with a variety of neuromodulation devices and eliminated the risk of iatrogenic lead damage 244 
or transfer of energy along the hardware to surrounding tissues. Additional observed 245 
advantages include reduced operating times, reduced damage to surrounding tissue and 246 
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therefore enhanced healing with reduced infection risk, improved operative exposure and the 247 
potential to facilitate revision procedures under local anaesthesia with associated cost 248 
savings. 249 
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LEGENDS 301 
Figure 1 :  AEX Generator & PEAK PlasmaBlade™ 302 
Figure 2 :  Intra-operative exposure of IPG using PlasmaBlade 303 
Figure 3 :  Copolymer lead, perpendicular device orientation, CUT mode 304 
A) PlasmaBlade Setting 5 305 
   B) Traditional electrosurgery unit, 30 watts.  306 
Figure 4:  Thermal Injury Profile comparing 307 
A) Scalpel 308 
B) PlasmaBlade 309 
C) Electrosurgery  310 
 311 
 312 
 313 
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Patient Anaesthesia Procedure Device 
1 LA DBS IPG Replacement Medtronic 
2 LA DBS IPG Replacement Medtronic 
3 GA DBS IPG Replacement Medtronic 
4 GA DBS IPG Replacement Medtronic 
5 GA DBS IPG Replacement Medtronic 
6 GA DBS IPG Replacement Medtronic 
7 GA DBS Wound Revision  Medtronic 3389 & Stimloc 
8 GA DBS Lead Revision Medtronic 95cm lead 
9 GA VNS IPG replacement LivaNova 104 
10 GA VNS IPG replacement LivaNova 106 
11 GA VNS IPG replacement LivaNova 106 
12 LA DBS IPG replacement Medtronic 
13 LA DBS IPG replacement Medtronic 
14 LA DBS IPG replacement Medtronic 
15 LA DBS IPG replacement Medtronic 
16 LA DBS IPG replacement Medtronic 
17 LA DBS IPG replacement Medtronic  
18 LA DBS IPG replacement Medtronic  
19 LA DBS IPG replacement Medtronic  
20 LA DBS IPG replacement Medtronic  
21 GA DBS IPG replacement Medtronic  
22 GA DBS IPG replacement Medtronic 
23 GA VNS IPG Replacement LivaNova Model 106 
24 GA VNS IPG Replacement LivaNova Model 106 
25 GA VNS IPG Replacement LivaNova Model 106 
26 GA VNS IPG Replacement LivaNova Model 106 
27 GA VNS IPG Replacement LivaNova Model 106 
28 GA ITB pump replacement Medtronic Synchromed II 
29 LA DBS IPG replacement Medtronic 
30 LA DBS IPG replacement St Jude Medical  
31 LA DBS IPG replacement Medtronic 
32 GA DBS IPG replacement Medtronic 
33 GA DBS IPG replacement Medtronic 
34 LA DBS IPG replacement Medtronic 
35 LA DBS IPG replacement Medtronic 
36 LA DBS IPG replacement Medtronic 
37 LA DBS IPG replacement Medtronic 
38 LA DBS IPG replacement Medtronic 
39 LA DBS IPG replacement Medtronic 
40 LA DBS IPG replacement Medtronic 
41 LA DBS IPG replacement Medtronic 
42 LA DBS IPG replacement Medtronic 
43 LA DBS IPG replacement Medtronic 
44 LA DBS IPG replacement Medtronic 
45 LA DBS IPG replacement Medtronic 
46 LA DBS IPG replacement Medtronic 
47 LA DBS IPG replacement Medtronic 
48 LA DBS IPG replacement Medtronic 
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49 LA DBS IPG replacement Medtronic 
50 LA DBS IPG replacement Medtronic 
51 LA DBS IPG replacement Medtronic 
52 LA DBS IPG replacement Medtronic 
53 LA DBS IPG replacement Medtronic 
54 LA DBS IPG replacement Medtronic 
55 LA DBS IPG replacement Medtronic 
56 LA DBS IPG replacement Medtronic 
57 LA DBS IPG replacement Medtronic 
 
Table 1: Indication for operation, type of anaesthesia and device manufacturer. 
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